# Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

> clinical trial · VERIFIED · 2026-06-12

Status: RECRUITING · Sponsor: City of Hope Medical Center · Condition: Recurrent Astrocytoma, IDH-Mutant, Grade 4

- Company: City of Hope Medical Center
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07544992

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.